Innovation in Plasma As a leader in plasma collection, CSL is uniquely positioned to innovate and improve the donor experience, raising the safety and effectiveness of the collection process, improving health equity in donor communities, and ensuring that the donor is rewarded for their contribution. CSL does this by recognising that it all begins with the donors who enable the life-saving therapies that patients depend on. Improving donor experience through individualised nomograms A notable initiative in the donor experience focus area is the Rika Plasma Donation System™’s Individualised Nomogram, iNomi™, which will allow plasma donors to donate the right amount of plasma based on weight, height and haematocrit, while maintaining the same collection time. iNomi™ received U.S. Food and Drug Administration (FDA) 510(k) clearance. CSL Plasma’s collaboration with Terumo Blood and Cell Technologies grants CSL exclusive rights to this technology, supporting its commitment to improving the donor experience. Improvements in targeted nomogram collections such as Nomogram A and Individualised Nomogram are important advances that will allow CSL to safely target a donor’s collection volume. This allows more plasma from some donors, thus helping to meet the growing patient needs. Donor safety is maintained, since weight and height will be considered, for example, smaller, shorter donors will give less than they did previously. The clinical trial to support the FDA clearance showed an average 10% increase in the volume of plasma collected per donation with an average collection time of less than 35 minutes. CSL anticipates receiving the software in FY25 with validation and change control beginning at that time. CSL Plasma will then work to transition those centres already on Rika devices to iNomi, and then transitioning all centers as the Rika rollout continues. Innovation Improving Plasma centres through Program REACH CSL continues to focus on ways to improve and innovate the donor experience. To this end, in June 2023 Program REACH, a Centre Improvement Program, was first deployed. CSL’s plasma donation network has grown significantly over the past ten years, from ~100 to nearly 350 centres. This continued growth and success depends upon delivering a consistent donor experience as well as a workplace of choice for employees. More investment in digital experience More donor acquisition via app Ease of donation experience via app Better centre operations Positive donor experience More plasma collected (or more Ig) 1 2 3 4 5 6 Plasma Flywheel Program REACH aims to set the foundation for continued long-term growth, operational optimisation, and consistency and reliability across the donor and employee experience. The program focuses broadly on four areas: improving the donor experience; improving the employee experience; standardising efforts and optimising ways of working. The goal is to understand root causes of challenges, and identify and implement solutions that drive sustainable improvement across the fleet. Aligned with the CSL Values of Superior Performance, Collaboration and Patient-Focus, Program REACH focuses on fulfilling CSL’s mission to provide life-saving medicine through plasma-derived therapies to patients in need. 30 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3